Up-regulation of CRKL by microRNA-335 methylation is associated with poor prognosis in gastric cancer

Jia-kui Zhang†, Yong-shuang Li†, Chun-dong Zhang and Dong-qiu Dai*

Abstract

Background: MicroRNAs have been suggested to play a vital role in regulating carcinogenesis, tumor progression and invasion. MiR-335 is involved in suppressing metastasis and invasion in various human cancers. However, the mechanisms responsible for the aberrant expression of miR-335 in gastric cancer (GC) remain unknown.

Methods: Expression of miR-335 in four GC cell lines and 231 GC tissues was determined by real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). DNA methylation status in the CpG islands upstream of miR-335 in GC cell lines and tissues was determined by methylation-specific PCR and bisulfite sequence-PCR. The effects of the demethylating agent 5-aza-2′-deoxycytidine on cell proliferation, apoptosis, cell cycle, migration, and invasion were investigated in GC cell lines.

Results: Cancer-specific methylation was detected in the upstream CpG-rich regions of miR-335, which dramatically silenced its transcriptional activity in GC cell lines and tissues. Low levels of miR-335 expression and high levels of miR-335 methylation in GC tissues were associated with poor clinical features and prognosis. Restoration of miR-335 expression in GC cells promoted cell apoptosis, inhibited tumor cell migration, invasion, and proliferation, and arrested the cell cycle at G0/G1 phase. Overexpression of miR-335 significantly reduced the activity of a luciferase reporter containing the 3′ untranslated region of V-crk avian sarcoma virus CT10 oncogene homolog-like (CRKL).

Conclusions: MiR-335 functions as a tumor suppressor and may be silenced by promoter hypermethylation. It plays a role in inhibiting tumor cell migration, invasion, and proliferation, arresting the cell cycle at G0/G1 phase, and promoting apoptosis in GC cells through targeting CRKL.

Keywords: Gastric cancer, MicroRNA, MiR-335, Methylation, Prognosis

Background

Gastric cancer (GC) is a common cancer and the second leading cause of cancer-related deaths worldwide [1, 2]. Despite considerable improvements in surgical techniques, innovations in clinical diagnostics, and the development of new chemotherapy regimens, the clinical outcome for patients with advanced GC remains poor [3]. A better understanding of the molecular mechanisms underlying GC will therefore improve the prevention, diagnosis, and therapy of this disease.

MicroRNAs (miRNAs) are a class of endogenous small non-coding RNAs of 21–25 nucleotides that regulate the expression of target genes in a post-transcriptional manner, leading to mRNA degradation or inhibition of translation through imperfect hybridization to the 3′ untranslated region (3′UTR) of the target mRNAs [4]. miRNAs are promising biomarkers and are involved in regulating diverse biologic processes. They can function as tumor suppressors or oncogenes, depending on the target gene.

MiR-335 expression was recently shown to be deregulated in several human cancers, and to act as a tumor suppressor in various tumor types [5–7]. Dysregulation...
of miRNAs can be caused by epigenetic modifications, including DNA methylation and the covalent modification of histone protein, which do not directly change the DNA sequence. DNA methylation is a heritable and enzyme-induced modification in humans. A high frequency of CpG dinucleotides is often found in the 5′UTR and first exon of most genes, and these dinucleotides control the expression of these genes by modulating their methylation status [8]. Methylation of CpG islands in the gene promoter has been strongly linked to the silencing of tumor-suppressor gene expression in cancer [9–14]. Several tumor-associated miRNAs have been reported to be silenced by aberrant hypermethylation of their promoter regions in various cancers, including miR-9, miR-137, miR-34b, miR-124a, miR-342, and miR-127 [10, 11, 15, 16]. However, the mechanisms responsible for the downregulation of miR-335 are unclear, and may involve various factors, including genetic and epigenetic modifications. Hypermethylation of the promoter region may also play an important role in silencing miR-335 in GC.

In the present study, we investigated the role of miR-335 methylation and expression in GC cell lines and tumor tissues, the clinicopathological and prognostic values of miR-335 methylation and expression in patients with GC, and the functional impact of ectopic miR-335 expression on GC cell invasion, cell cycle, apoptosis, and proliferation.

Methods

Clinical tissue samples and cell lines

A total of 231 pairs of fresh GC and adjacent non-tumor gastric tissues were obtained from patients with a diagnosis of primary GC who underwent elective surgery at The Cancer Institute of China Medical University (Shenyang, China) between June 2009 and June 2011, after obtaining written informed consent. None of the patients had received chemotherapy or radiotherapy before surgery. The use of tissues for this study was approved by the ethics committee of The Fourth Affiliated Hospital of China Medical University. The median age of the patients (123 men and 108 women) was 61 years (range 26–85 years). Survivors were followed up by phone or mail for a median period of 31 months (range 3–60 months). The study parameters included age, sex, stage, histological grade, macroscopic type, Lauren’s grade, venous invasion, peritoneal dissemination, tumor size, depth of invasion, lymph node metastasis, invasion into lymphatic vessels, and distant metastasis. TNM classification definitions were made according to the American Joint Committee on Cancer TNM staging system (7th edition). Cancer histological grade was assessed according to the criteria set by the World Health Organization. Fresh samples were snap frozen in liquid nitrogen immediately after resection and stored at −80 °C.

The immortalized normal gastric mucosal epithelium cell line (GES-1) and four GC cell lines (SGC-7901, MKN-45, BGC-823, and AGS) were purchased from Shanghai Institutes for Biological Sciences, Chinese Academy of Science (Shanghai, China) in July 2014. All of the cell lines have been tested and authenticated by STR profiling (ATCC) in July 2014. All cells were cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 100 µg/mL streptomycin, and 100 U/mL penicillin in a humidified cell incubator at 37 °C with an atmosphere of 5% CO₂. Cells were treated with 3 µmol/L 5-aza-2′-deoxycytidine (5-aza; Sigma–Aldrich, St Louis, MO, USA) for 72 h to inhibit DNA methyltransferase (DNMT) activity. Cells treated with dimethyl sulfoxide served as a control. An initial report indicated that these conditions could achieve maximal demethylation with minimal toxic effects [17]. SGC-7901 cells were plated 1 day before transfection using Lipofectamine 2000 reagent (Invitrogen, USA) according to the manufacturer’s instructions. Cells were harvested for further experiments after 24 or 48 h.

Extraction of total RNA and real-time polymerase chain reaction

Total RNA was extracted from cell lines using RNAiso Plus (Takara Bio Inc., Shiga, Japan), according to the manufacturer’s protocol. The concentration was determined by ultraviolet–visible spectrophotometry (A260/A280 > 1.9). Quantitative polymerase chain reaction (PCR) was performed using an All-in-One miRNA quantitative RT-PCR Detection Kit (GeneCopoeia, Rockville, MD) according to the manufacturer’s instructions. The primer sequences were as follows: (forward) 5′-TCAAG AGCAATACGAAAAATGTG-3′ (reverse) 5′-GCTGTC AAGGATACGCCTACGT-3′ (miR-335) and (forward) 5′-CGCTTTGGCCAGCACATATACTGC-3′, 5′-TTACGGAAT TTGCGTGTCAT-3′ (U6). U6 mRNA levels were used as an endogenous reference for normalization. Results were normalized to the concentration of U6 RNA and calculated using the 2⁻ΔΔC_T method, where ΔC_T was the difference in threshold cycle (C_T) values.

For detection of V-crk avian sarcoma virus CT10 oncogene homolog-like (CRKL) mRNA, first-strand cDNA was synthesized using a High-Capacity cDNA Reverse Transcription Kit (ABI, USA). RT-primers for CRKL mRNA were synthesized as follows: 5′-CATTTCC CGGGCGGCTCTCTC-3′ (forward) and 5′-CACGGCT TAGCCCCGCGACAC-3′ (reverse) by Sangon Biotech Company (Shanghai, China). Real-time quantitative PCR (qRT-PCR) was performed according to the TaqMan
Gene Expression Assays protocol (ABI, USA). The relative quantification of CRKL mRNA in cell lines was normalized using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) by the 2−ΔΔCT method. The PCR program was designed as follows: 95 °C for 10 min, followed by 35 cycles of 95 °C for 15 s, 60 °C for 30 s, and 72 °C for 45 s. All qRT-PCRs were performed in triplicate.

Luciferase assay
CRKL was predicted as a potential target of miR-335 by bioinformatics analysis (TargetScan, http://www.targetscan.org/). Plasmids containing wild-type and mutant Luc-CRKL 3′UTR were synthesized (GeneCopoeia) and used in luciferase reporter assays. These plasmids contained firefly luciferase and Renilla luciferase as tracking genes. Luciferase activity assays were performed following the manufacturer’s protocols. Briefly, SGC-7901 cells were seeded in six-well plates, cotransfected with miR-335 mimic or NC and lentiviral constructs containing the target gene with wild-type or mutated 3′UTR, using Lipofectamine 2000. Firefly and Renilla luciferase activities were measured 48 h after transfection using a LucPair miR Luciferase Assay Kit (GeneCopoeia) according to the manufacturer’s recommendations. Activities were normalized to Renilla luciferase. Results represent three independent experiments, each performed in triplicate.

Extraction of genomic DNA and bisulfite modification
Genomic DNA was isolated from the cultured cells and specimens using a Universal Genomic DNA Extraction Kit Ver3.0 (Takara Bio Inc.). DNA concentration and purity were controlled by ultraviolet–visible spectrophotometry (1.8 < A260/A280 < 2.0). Genomic DNA (2 µg) was then subjected to bisulfite conversion using an EZ DNA Methylation-Gold Kit (Zymo Research Corporation, Orange, CA, USA). The bisulfite conversion reaction was incubated in a PCR thermocycler at 98 °C for 10 min, followed by 64 °C for 2.5 h, with a final incubation at 4 °C for up to 20 h. The modified DNA samples were dissolved in ddH₂O and stored at −80 °C.

DNA methylation bisulfite-modified sequencing
The sequence of miR-335 was searched using the University of California Santa Cruz’s Genome Bioinformatics resource [18]. Scanning for CpG islands in the submitted sequence identified four CpG islands in Methprimer (http://www.urogene.org/index.html). The Berkeley Drosophila Genome Project (BDGP) (http://fruitfly.org:9005/seq_tools/promoter.html) submitted three promoter regions with scores > 0.90: 128–178 base pairs (bp), 935–985 bp, and 1740–1790 bp. We confirmed that the promoter of miR-335 lay within the range of the CpG islands.

Bisulfite-modified sequencing (BSP) primers were designed using Methyl Primer Express® software (v 1.0; Thermo Fisher Scientific, USA): forward 5′-TAAAGGGG GTTTGTTTTAAATT-3′ and reverse 5′-CCCACA ACTACCCACAAAC-3′. The whole process was as follows: DNA methylation bisulfite modification; PCR amplification, electrophoresis, and retrieval; PCR products connected to the pUC18-T vector and transformation; blue/white plaque selection; extraction of plasmids; and finally sequencing of the DNA. The sequencing process was performed by Sangon Biotech (Shanghai, PR China) with genomic DNA from the cell lines and sequencing primers provided by our group.

Methylation-specific PCR
We designed primers for methylation-specific PCR (MSP) using Methyl Primer Express software: methylated forward 5′-GGTTTTAAAAGTGCGTTTTATTC-3′, reverse 5′-AUCTACACCTCCTCGATTA-3′; and unmethylated forward 5′-GGTTTTAAAAAGTTGCTT TTAATT-3′, reverse 5′-AACTACACCACTCCA ACATA-3′. The amplicon sizes were 125 and 127 bp for methylated and unmethylated products, respectively. We used treated DNA in PCR amplification with TaKaRa Taq Hot Start Version (code number DR007A; Takara Bio Inc.). The PCRs were conducted under the following thermocycling conditions: 5 min at 94 °C, 40 cycles of 30 s at 94 °C, 30 s at 58 °C, 30 s at 72 °C, and a final incubation at 72 °C for 10 min. All PCRs were performed with negative and positive controls using completely methylated and unmethylated human control DNA, respectively, and water. Aliquots of 5 µL of the total 20 µL of the PCR mixture were loaded onto 3% agarose gels, stained with ethidium bromide, and visualized directly under ultraviolet illumination. MSP assays were repeated at least three times for each sample to determine the reproducibility of the results.

Western blot
Cells were lysed using RIPA lysis buffer containing Protease Inhibitor Cocktail (Pierce, USA), and the protein concentration was measured by BCA Protein Assay Kit (Pierce). Proteins were electrophoresed and electrotransferred. The membranes were probed using antibodies against CRKL (1:1000) and GAPDH (1:5000), with horseradish peroxidase-conjugated secondary antibodies. Protein quantities were detected using GAPDH as a loading control.

Transwell cell migration and Matrigel invasion assays
We determined the invasion ability of 5-aza-treated SGC-7901 and NC cells in vitro by Transwell cell
migration and Matrigel invasion assays. Cells were plated in 24-well Transwell plates (8 mm pore size; Corning, NY, USA) to measure their migratory and invasive abilities. For Transwell migration assays, 2.5 × 10⁵ cells were added to the top chamber lined with a non-coated membrane. For invasion assays, chamber inserts were coated with 200 mg/mL Matrigel (BD Biosciences, San Jose, CA, USA), dried overnight under sterile conditions, and 5 × 10⁴ cells were then placed in the top chamber. In both assays, cells were suspended in medium without serum or growth factors, and medium supplemented with serum was used as a chemoattractant in the lower chamber. After 24 h incubation at 37 °C with 5% CO₂, cells were suspended in medium without serum or growth factors, and medium supplemented with serum was used as a chemoattractant in the lower chamber. After 24 h incubation at 37 °C with 5% CO₂, the number of cells that had migrated to the basolateral side of the membrane was quantified by counting 16 independent symmetrical visual fields under a microscope. Cell morphology was observed by staining with hematoxylin–eosin. Assays were conducted in five independent experiments.

Cell proliferation assay and cell cycle analysis
The proliferation abilities of 5-aza-treated SGC-7901, MKN-45 and their NC cells were determined by MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay using a Cell Proliferation Kit I (Roche Applied Science), according to the manufacturer’s instructions. For cell cycle analysis, cells were treated by ethanol fixation, RNase A, and propidium iodide (PI) staining, and then detected by flow cytometry using a FACScalibur (Becton–Dickinson, USA). Cell populations in the G0/G1, S, and G2/M phases were quantified by Modfit software (Becton–Dickinson), allowing for cell debris and fixation artifacts.

Cell apoptosis analysis
Cell apoptosis rate was calculated using an Annexin V-FITC Apoptosis Detection Kit I (BD Pharmingen, USA) according to the product instructions. Briefly, cells were washed with phosphate-buffered saline and resuspended in 1× Binding Buffer at a concentration of 1 × 10⁶ cells/mL, followed by the addition of 5 µL fluorescein isothiocyanate (FITC)–Annexin V and 5 µL PI to 100 µL of the cell suspension, incubation for 15 min in the dark, and the addition of 400 µL 1× Binding Buffer. Apoptosis was analyzed by flow cytometry (FACScalibur, Becton–Dickinson) using CellQuest software (Becton–Dickinson). Apoptotic cells were defined as Annexin V-FITC-positive, PI-negative cells.

Wound-healing assay
5-Aza-treated SGC-7901 and NC cells were grown to confluence. A wound was made through the monolayer using a p20 pipette tip, and the migration rate was calculated according to the equation: percentage wound healing = [(wound length at 0 h) – (wound length at 4, 6, 20, or 27 h)]/(wound length at 0 h) × 100. Two independent experiments were performed.

Statistical analysis
Statistical analyses were performed using SPSS for Windows statistical software, version 19.0 (SPSS, Chicago, IL, USA). Data are presented as the mean ± standard deviation (SD) from at least three independent experiments. Differences between groups were analyzed using Student’s t tests and nonparametric Mann–Whitney U tests. The relationship between miR-335 expression levels and methylation status in gastric tissues was calculated using χ² tests (2 × 2 table, Pearson’s analysis). Correlations between methylation status, miR-335 expression levels, and clinicopathologic parameters were analyzed by χ² with Mann–Whitney U tests for two groups and Kruskal–Wallis tests for three or more groups. Survival curves were plotted using the Kaplan–Meier method and survival differences were assessed using the log-rank test. Univariate and multivariate Cox proportional hazards models were used to assess survival results. Disease-free survival (DFS) was measured from the date of surgery to the time of recurrence, death, or censoring. All P values were two-sided, and differences were considered to be statistically significant when P < 0.05.

Results
Downregulation of miR-335 in human GC cell lines
We examined the expression levels of miR-335 in five human gastric cell lines (SGC-7901, MKN-45, BGC-823, AGS, and GES-1) by qRT-PCR. MiR-335 was downregulated in GC cell lines (SGC-7901, MKN-45, BGC-823, and AGS) compared with normal gastric epithelial cells (GES-1) (MKN-45, 0.154 ± 0.016-fold, P < 0.01; SGC-7901, 0.138 ± 0.013-fold, P < 0.01; BGC-823, 0.432 ± 0.076-fold, P < 0.01; AGS, 0.749 ± 0.072-fold, P = 0.01) (Fig. 1a).

Relative expression levels of miR-335 in human GC tissues and correlation with clinicopathological characteristics
To determine if miR-335 expression was associated with GC, we compared miR-335 expression levels in a large cohort of 231 primary GC tissues with levels in pair-matched adjacent non-tumor tissues, using qRT-PCR. MiR-335 levels were significantly downregulated in GC tissues compared with paired adjacent non-tumor tissues (P < 0.001; Fig. 1b). We divided the 231 patients with GC into high-miR-335-expression (n = 116) and low-miR-335-expression groups (n = 115), according to miR-335 expression levels above or below the median value, respectively. Low miR-335 expression was significantly
associated with tumor size \((P = 0.030)\), venous invasion \((P = 0.027)\), peritoneal dissemination \((P = 0.033)\), lymph node metastasis \((P = 0.033)\), poor \(pT\) stage \((P = 0.040)\), poor \(pN\) stage \((P = 0.038)\), poor TNM stage \((P = 0.005)\), and invasion into lymphatic vessels \((P = 0.041)\) (Table 1).

We also analyzed the association between miR-335 expression and survival duration using Kaplan–Meier analysis with the log-rank test. High miR-335 expression was significantly associated with better DFS \((P = 0.013)\) (Fig. 2a).

**CRKL levels in GC cells and role as target of miR-335**

To identify the potential target genes of miR-335, we integrated bioinformatic algorithms using the publicly available database TargetScan (http://www.targetscan.org). Among a total of 255 genes that were potentially targeted by miR-335 (Fig. 3a), CRKL may contribute to the metastasis, invasion, and proliferation of GC.

We detected CRKL expression in four GC cell lines (SGC-7901, MKN-45, BGC-823, AGS) and one immortalized gastric epithelial cell line (GES-1) by qRT-PCR and western blotting. CRKL mRNA levels were similar in all four GC cell lines and GES-1 cells \((P > 0.05)\) (Fig. 1c). However, western blot analysis indicated that CRKL protein expression levels were increased in GC cell lines compared with GES-1 cells (Fig. 1d), suggesting post-transcriptional regulation of CRKL expression in GC cells.

To validate the miRNA–target interactions, we evaluated CRKL expression in SGC-7901 cells transfected with either miR-335 mimic or NC. Overexpression of miR-335 dramatically suppressed endogenous CRKL at the protein level compared with NC, as demonstrated by western blot and qRT-PCR (Fig. 3c–f). To confirm if CRKL was regulated by miR-335 through direct binding to its 3′UTR, wild-type and mutant CRKL 3′UTRs were constructed and cloned downstream of the luciferase gene in a pGL3-control vector, followed by luciferase assay in SGC-7901 cells. The wild-type 3′UTR reporter construct was associated with significantly lower luciferase
activity in cells expressing miR-335 compared with those expressing NC miRNA. In contrast, there was no significant difference in relative luciferase activities of pGL3-CRKL-MUT reporters in SGC-7901 cells transfected

![Graphs](image)

**Fig. 2** Kaplan–Meier plots of disease-free survival in relation to miR-335 expression and methylation levels. **a** Kaplan–Meier disease-free survival curves in relation to miR-335 expression levels. Disease-free survival of patients with low miR-335 expression (n = 115) was significantly lower than that of patients with high miR-335 expression (n = 116; log-rank test; P = 0.013). **b** Kaplan–Meier disease-free survival curves in relation to miR-335 methylation levels. Disease-free survival of patients with hypermethylation of miR-335 (n = 127) was significantly lower than that of patients with hypomethylation of miR-335 (n = 104; log-rank test; P = 0.035)

| Variable                              | Low expression (n = 115) | High expression (n = 116) | P   |
|---------------------------------------|--------------------------|---------------------------|-----|
| Age                                   |                          |                           | 0.728|
| >55                                   | 87                       | 76                        | 90  |
| ≤55                                   | 28                       | 24                        | 26  |
| Sex                                   |                          |                           | 0.641|
| Male                                  | 63                       | 55                        | 60  |
| Female                                | 52                       | 45                        | 56  |
| Histological grade                    |                          |                           | 0.616|
| Well                                  | 39                       | 34                        | 43  |
| Poor                                  | 76                       | 66                        | 73  |
| Tumor size (cm)                       |                          |                           | 0.030*|
| ≤3.5                                  | 24                       | 21                        | 39  |
| >3.5                                  | 91                       | 79                        | 77  |
| Macroscopic type                      |                          |                           | 0.702|
| Early stage                           | 3                        | 3                         | 3   |
| Borrmann I + II                      | 10                       | 9                         | 14  |
| Borrmann III + IV                    | 102                      | 88                        | 99  |
| Lauren’s grade                        |                          |                           | 0.813|
| Intestinal                            | 36                       | 31                        | 38  |
| Diffuse                               | 79                       | 69                        | 78  |
| Venous invasion                       |                          |                           | 0.027*|
| Absent                                | 81                       | 70                        | 96  |
| Present                               | 34                       | 30                        | 20  |
| Liver metastasis                      |                          |                           | 0.669|
| Absent                                | 105                      | 91                        | 104 |
| Present                               | 10                       | 9                         | 12  |
| Peritoneal dissemination              |                          |                           | 0.027*|
| Absent                                | 95                       | 83                        | 107 |
| Present                               | 20                       | 17                        | 9   |
| pT stage                              |                          |                           | 0.040*|
| T1                                    | 1                        | 1                         | 5   |
| T2                                    | 20                       | 17                        | 24  |
| T3                                    | 30                       | 26                        | 42  |
| T4                                    | 64                       | 56                        | 45  |
| pN stage                              |                          |                           | 0.038*|
| N0 + N1                               | 29                       | 25                        | 44  |
| N2 + N3                               | 86                       | 75                        | 72  |
| Metastasis lymph node                 |                          |                           | 0.033*|
| Negative                              | 26                       | 23                        | 41  |
| Positive                              | 89                       | 77                        | 75  |
| Invasion into lymphatic vessels       |                          |                           | 0.041*|
| Negative                              | 87                       | 76                        | 100 |
| Positive                              | 28                       | 24                        | 16  |
| AJCC stage                            |                          |                           | 0.005*|
| I + II                                | 48                       | 42                        | 70  |
| III + IV                              | 67                       | 58                        | 46  |

*Based on Pearson χ² test and Fisher exact test

*Significantly different

pT primary tumor, pN primary node, AJCC American Joint Committee on Cancer

*Statistically significant
with miR-335 or NC miRNA (Fig. 3b). Overall, these results indicated that CRKL was directly targeted by miR-335, and that CRKL expression in GC was negatively regulated by miR-335.

Downregulation of miR-335 by DNA methylation in GC cell lines and tissues

Tumor suppressor miRNAs, including miR-335, have been reported to be silenced by aberrant DNA
hypermethylation. We therefore investigated the mechanisms whereby miR-335 functions in GC cells, with an emphasis on epigenetics. We determined if miR-335 expression was silenced by DNA methylation by examining the reactivation of miR-335 expression in GC and NC cells following treatment with the demethylating agent 5-aza. MiR-335 expression levels recovered by 2–3-fold after 5-aza treatment (Fig. 4a). We also detected CRKL expression levels in 5-aza-treated GC and NC cells by qRT-PCR and western blot. CRKL mRNA levels were similar in 5-aza-treated and NC cells (P > 0.05) (Fig. 4b), but CRKL protein levels were significantly reduced after 5-aza treatment, as indicated by western blotting (Fig. 4c). Furthermore, we detected CpG island methylation of miR-335 in GC cell lines by BSP analysis of multiple clones in the cell lines. Bisulfite sequencing in all four GC cell lines confirmed marked methylation of the promoter region of miR-335 (Fig. 4d).

DNA methylation levels in GC cell lines and tissues were analyzed by MSP. Hypermethylation and hypomethylation of PCR products were detected by electrophoresis. All four GC cell lines showed hypermethylation (Fig. 5a). Among the 231 GC tissue samples, 127 samples showed hypermethylation (55%) and 104 samples showed hypomethylation (45%) (Fig. 5b). The MSP results were used to analyze correlations between miR-335 expression and clinicopathologic features in patients with GC.

We also analyzed the correlations between miR-335 methylation status and clinicopathologic characteristics. Hypermethylation of the miR-335 gene promoter region was associated with tumor size (P = 0.004), miR-335 expression level (P < 0.001), and invasion into lymphatic...
vessels ($P = 0.001$) (Table 2). These results indicated that patients with GC with low miR-335 expression, metastatic lymph nodes, invasion into lymphatic vessels, and large tumor size may have hypermethylation in the miR-335 gene promoter region.

We also analyzed the association between miR-335 methylation status and survival duration using Kaplan–Meier analysis with the log-rank test. Patients were divided into hypermethylation ($n = 127$) and hypomethylation ($n = 104$) groups. Kaplan–Meier estimation indicated that hypomethylation of miR-335 was significantly associated with better DFS ($P = 0.035$) (Fig. 2b).

**Effects of ectopic miR-335 expression on cell apoptosis, proliferation, migration, and invasion, and cell cycle in SGC-7901 cells**

We investigated the contribution of DNA methylation of miR-335 to gastric carcinogenesis by determining the effect of DNA methylation of miR-335 on the phenotype of GC cells. SGC-7901 and MKN-45 cells were treated with 5-aza at a final concentration of 3 μmol/L, and miR-335 expression was analyzed after 72 h. 5-Aza treatment increased miR-335 expression in SGC-7901 and MKN-45 cells, as confirmed by qRT-PCR (Fig. 4a). The effect on CRKL expression was validated by western-blot analysis (Fig. 4c). The migration and invasive capacities of SGC-7901 cells, assessed by Transwell and wound-healing assays, respectively, were significantly reduced following restoration of miR-335 expression (Figs. 6a, b, 7a, b). The proliferation abilities of 5-aza-treated, NC-treated, and parental gastric cancer cells were assessed by MTT assay. Cell proliferation of SGC-7901 and MKN-45 cells was significantly reduced by 5-aza compared with NC and parental cells (Fig. 7c). We also investigated the effect of restoration of miR-335 expression on GC cell cycle. The cell cycle in SGC-7901 cells was significantly arrested at G0/G1 phase when miR-335 expression was restored, as shown by flow cytometry (Fig. 8a, b). The percentage of SGC-7901 cells in G0/G1 phase increased from 62.43 to 81.69% ($P < 0.05$), S phase cells decreased from 28.83 to 10.62% ($P < 0.05$), and G2/M phase cells decreased from 8.74 to 7.41% ($P < 0.05$).

To clarify the biological functions of miR-335 in GC, we investigated its effect on GC cell apoptosis. The apoptosis rates of NC and 5-aza-treated cells were 9.61 and 16.11%, indicating that restoration of miR-335 expression significantly increased apoptosis of GC cells ($P < 0.01$).

**Discussion**

Epigenetic mechanisms are important for regulating cell growth and development in mammals. miRNAs represent a class of small non-coding RNAs that regulate gene expression at the post-transcriptional level, and subsequently control crucial physiological processes. Aberrant expression of miRNAs has recently been reported to have an impact on human carcinogenesis. Expression of miRNAs may be regulated by various processes, including DNA methylation and histone modification, [17, 19, 20] DNA copy abnormalities [21], mutation [22], failure of post-transcriptional regulation [23], regulation by transcription factors [24], and defective miRNA biogenesis pathways [25]. DNA methylation is one of the most important types of epigenetic modifications, and has frequently been reported to regulate gene transcription.
Promoter hypermethylation is associated with inhibition of gene transcription and function of tumor suppressor genes. Several tumor-suppressive miRNAs are known to be silenced by aberrant DNA methylation of their promoter regions in human cancers, including miR-34, miR-129, miR-137, miR-193a, miR-203, and miR-148a [27–30]. In this study, we focused on miR-335 silencing by methylation in GC cells.

MiR-335 is transcribed from the genomic region of chromosome 7q32.2 and has been shown to be aberrantly expressed in malignant tumors, and to play crucial roles in tumor initiation and progression [31]. Cao et al. [5] observed that miR-335 expression was reduced in epithelial ovarian cancer tissue samples, especially in omental metastases, and low miR-335 levels emerged as an independent prognostic factor for poor overall and relapse-free survival; Wang et al. [32] also identified miR-335 as a tumor suppressor by targeting the ROCK1 gene and inhibiting osteosarcoma cell migration and invasion. However, the detailed expression pattern and potential role of miR-335 in GC remains unclear. Yan et al. [33] reported that GC patients with high levels of miR-335 had a high frequency of recurrence. In contrast, Xu et al. [34] reported that miR-335 was dramatically downregulated in GC cell lines, and low expression of miR-335 was associated with poor pT stage, poor pN stage, and invasion into lymphatic vessels. Further studies are therefore needed to clarify the biological functions and mechanisms of miR-335 in GC.

The results of the current study showed that miR-335 was dramatically downregulated in GC cell lines and tissue specimens, suggesting that low expression of miR-335 was significantly associated with GC. Clinicopathological analysis also found that miR-335 expression was negatively correlated with tumor size, venous invasion, peritoneal dissemination, lymph node metastasis, poor pT stage, poor pN stage, poor TNM stage, and invasion into lymphatic vessels, while low

### Table 2 Association between the promoter region methylation status of miR-335 and clinicopathologic features in patients with gastric cancer

|                          | Hypermethylation (n = 127) | Hypermethylation (n = 104) | P     |
|--------------------------|----------------------------|----------------------------|-------|
| **Age**                  |                           |                            | 0.830 |
| >55                      | 98                        | 77                         | 79    | 76  |
| ≤55                      | 29                        | 23                         | 25    | 24  |
| **Sex**                  |                           |                            | 0.371 |
| Male                     | 71                        | 56                         | 52    | 50  |
| Female                   | 56                        | 44                         | 52    | 50  |
| **Histological grade**   |                           |                            | 0.765 |
| Well                     | 44                        | 35                         | 38    | 37  |
| Poor                     | 83                        | 65                         | 66    | 63  |
| **Tumor size (cm)**      |                           |                            | 0.004*|
| ≤3.5                     | 25                        | 20                         | 38    | 37  |
| >3.5                     | 102                       | 80                         | 66    | 63  |
| **Macroscopic type**     |                           |                            | 0.843 |
| Early stage              | 4                         | 3                          | 2     | 2   |
| Bormann I + II           | 13                        | 10                         | 11    | 11  |
| Bormann III + IV         | 110                       | 87                         | 91    | 87  |
| **Lauren’s grade**       |                           |                            | 0.347 |
| Intestinal               | 44                        | 35                         | 30    | 29  |
| Diffuse                  | 83                        | 65                         | 74    | 71  |
| **Venous invasion**      |                           |                            | 0.922 |
| Absent                   | 97                        | 76                         | 80    | 77  |
| Present                  | 30                        | 24                         | 24    | 23  |
| **Liver metastasis**     |                           |                            | 0.622 |
| Absent                   | 116                       | 91                         | 93    | 89  |
| Present                  | 11                        | 9                          | 11    | 11  |
| **Peritoneal dissemination** |                       |                            | 0.223 |
| Absent                   | 108                       | 85                         | 94    | 90  |
| Present                  | 19                        | 15                         | 10    | 10  |
| **pT stage**             |                           |                            | 0.434 |
| T1                       | 3                         | 2                          | 3     | 3   |
| T2                       | 23                        | 18                         | 21    | 20  |
| T3                       | 35                        | 28                         | 37    | 36  |
| T4                       | 66                        | 52                         | 43    | 41  |
| **pN stage**             |                           |                            | 0.240 |
| N0 + N1                  | 36                        | 28                         | 37    | 36  |
| N2 + N3                  | 91                        | 72                         | 67    | 64  |
| **Metastasis lymph node**|                           |                            | 0.058 |
| Negative                 | 30                        | 24                         | 37    | 35  |
| Positive                 | 97                        | 76                         | 67    | 65  |
| **Invasion into lymphatic vessels** |                    |                            | 0.001*|
| Negative                 | 93                        | 73                         | 94    | 90  |
| Positive                 | 34                        | 27                         | 10    | 10  |
| **AJCC stage**           |                           |                            | 0.197 |
| I + II                   | 60                        | 47                         | 58    | 56  |
| III + IV                 | 67                        | 53                         | 46    | 44  |

| **Table 2 continued**    | Hypermethylation (n = 127) | Hypermethylation (n = 104) | P     |
|--------------------------|----------------------------|----------------------------|-------|
| **MiR-335 level**        |                           |                            | <0.001*|
| Low expression           | 78                        | 61                         | 37    | 36  |
| High expression          | 49                        | 39                         | 67    | 64  |

Based on Pearson χ² test and Fisher exact test

pT primary tumor, pN primary node, AJCC American Joint Committee on Cancer

* Statistically significant during tumorigenesis [26].
expression of miR-335 was associated with shorter DFS in GC patients.

In the present study, we analyzed the methylation status of miR-335 in GC cell lines using BSP and MSP. Hypermethylation of the promoter region of miR-335 was relatively common in GC cell lines, and was also detected in 55% of 231 GC tissue specimens by MSP. We analyzed the correlation between methylation status and miR-335 expression in GC tissues and showed that downregulated expression of miR-335 was significantly correlated with CpG island DNA hypermethylation in the promoter region. We also showed that miR-335 methylation status was associated with tumor size and invasion into lymphatic vessels in a large sample of patients with GC. These results suggest that promoter hypermethylation might repress miR-335 expression, and that low expression might in turn contribute to metastasis, proliferation, and invasion in GC. Furthermore, we confirmed that miR-335 expression in GC cells was upregulated by the DNA methylation inhibitor 5-aza.

Functional studies demonstrated that restoration of miR-335 reduced cell proliferation, migration, and invasion, arrested the cell cycle, and increased GC cell apoptosis, indicating a potentially suppressive role for miR-335 in GC. We further explored the mechanisms whereby miR-335 regulates tumor invasion, metastasis, proliferation, cell cycle, and apoptosis in GC by identifying miR-335 targets in GC carcinogenesis and progression. We searched for direct target genes by bioinformatics miRNA–mRNA 3′UTR matching, and found that CRKL included a putative miR-335-binding site within its 3′UTR. CRKL acts as a transcriptional activator in Bcr-Abl-expressing cells, and constitutes the major tyrosine phosphorylated protein in chronic myelogenous leukemia [35]. Protein-expression analysis of activated phosphorylated CRKL in normal and
malignant tissues indicated that CRKL was associated with malignant transformation, and was selectively up-regulated in numerous epithelial tumors, including gastric, prostate, ovary, and colon cancers [36]. Yeung et al. [37] found that CRKL was over-expressed in rhabdomyosarcoma tissues and cell lines, and was involved in rhabdomyosarcoma tumor growth. Research on non-small cell lung cancer cell lines by Kim et al. [38] showed that CRKL was amplified in diverse oncogenic lung cancer phenotypes, and RNA interference-mediated knock-down of CRKL could significantly suppress the proliferation, survival, and migration of lung cancer cell lines. Natsume et al. [39] recently observed that CRKL protein was amplified in GC, and this report suggests that CRKL may be a critical molecule and a possible therapeutic target involved in the initiation and development of GC.

Our experimental results confirmed that CRKL was a target of miR-335 in GC cells. Overexpression of miR-335 significantly reduced the activity of a luciferase reporter containing the 3’UTR sequence of CRKL, while mutation of the seed region sites in the 3’UTR abolished the regulatory effect of miR-335. Furthermore, restoration of miR-335 down-regulated CRKL protein expression post-transcriptionally. These study thus clearly suggest that miR-335 may directly regulate CRKL expression by inducing mRNA degradation and translational suppression. Collectively, down-regulation of miR-335 may thus contribute to gastric carcinogenesis, at least partly via up-regulation of CRKL.

**Conclusion**

This study demonstrated for the first time that miR-335 was dramatically down-regulated in GC, and revealed that low expression of miR-335 was associated with tumor size, venous invasion, peritoneal dissemination, lymph node metastasis, poor pT stage, poor pN stage, poor TNM stage, invasion into lymphatic vessels, and shorter DFS. Moreover, restoration of miR-335 suppressed GC cell proliferation, migration, and invasion, arrested the cell cycle, and increased GC cell apoptosis. MiR-335 thus functions as a tumor suppressor in GC. To the best of our knowledge, this study also provides the first evidence for associations between hypermethylation of the miR-335 promoter region and its expression, and between hypermethylation status and shorter DFS, invasion into lymphatic vessels, and large tumor size, which could be predictive factors for tumor prognosis and
biological behavior in GC tissues. The effects of miR-335 on GC cell migration, invasion, and proliferation observed in this study may be partly due to its regulation of CRKL. These data warrant further investigations of the miR-335/CRKL axis as a prospective therapeutic target in the treatment of GC. Further large-scale and long-term follow-up studies focusing on the methylation status of miR-335 in GC should be undertaken in the future.

Abbreviations
GC: gastric cancer; MiR: microRNA; qRT-PCR: real-time quantitative reverse transcriptase-polymerase chain reaction; DNMT: DNA methyltransferase; 5-Aza: 5-aza-2′-deoxycytidine; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; DFS: disease-free survival; CRKL: V-crk avian sarcoma virus CT10 oncogene homolog-like.

Authors’ contributions
JZ carried out study concepts, study design, data acquisition and interpretation, manuscript preparation and editing, participated in the real-time quantitative reverse transcriptase-PCR, Methylation-specific PCR, bisulfite sequence-PCR (BSP), Luciferase reporter assay and western blot. YL followed up the patients, collected the data, analyzed the data, participated in the in vitro migration and invasion assays, cell cycle analysis, cell apoptosis analysis wound-healing assay. CZ carried out data acquisition, manuscript review, participated in the in vitro migration and invasion assays and cell cycle analysis. DD carried out study concepts, study design, manuscript preparation and editing, manuscript review, participated in the bisulfite sequence-PCR (BSP), Luciferase reporter assay and western blot. All authors read and approved the final manuscript.

Acknowledgements
The authors would like to thank the surgeons and general practitioners for their participation in contact with patients. We also thank Huai-ya Hu (Department of Neuroscience and Physiology, SUNY Upstate Medical University), Zhen Zhang (Department of Biochemistry and Molecular Biology, University of Kansas Medical Center), Xiao-mei Wu (Department of Clinical Epidemiology and Center of Evidence Based Medicine, The First Hospital of China Medical University) and Fang Li-li (Department of Anesthesiology, The Second Affiliated Hospital Zhejiang University School of Medicine) for their careful reading and kind suggestion.

Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
Please contact author for data requests.

Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was conducted with the permission of the Ethics Committee of China Medical University (Shenyang, China). Informed consent was obtained from all individual participants included in the study.

Received: 27 September 2016 Accepted: 28 January 2017
Published online: 16 February 2017

References
1. Bickenbach K, Strong VE. Comparisons of gastric cancer treatments: east vs. west. J Gastric Cancer. 2012;12:55–62.
2. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354–62.
3. Moon YW, Jeung HC, Rha SY, Yoo NC, Roh JK, Noh SH, Kim BS, Chung HC. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single Korean institute. Ann Surg Oncol. 2007;14:2730–7.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
5. Cao J, Cai J, Huang D, Han Q, Chan Y, Qian D, et al. MiR-335 represents an independent prognostic marker in epithelial ovarian cancer. Am J Clin Pathol. 2014;141(3):437–42.
6. Gadducci A, Sergiampietri C, Lanfredini N, Guiggi I. MicroRNAs and ovarian cancer: the state of art and perspectives of clinical research. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2014. doi:10.3109/09513590.2013.871525.
7. Gong M, Ma J, Guillemette R, Zhou M, Yang Y, Li J, et al. MiR-335 inhibits small cell lung cancer bone metastases via IGFIR and RANKL pathways. Mol Cell Res. 2014;12(1):101–10.
8. Wang Y, Leung FC. An evaluation of new criteria for CpG islands in the human genome as gene markers. Bioinformatics (Oxford, England). 2004;20:1170–7.
9. Sharma S, Kelly TK, Jones PS. Epigenetics in cancer. Carcinogenesis. 2004;25:281–89.
10. Oue N, Kuraoka K, Kuniyasu H, Yokozaki H, Wakikawa A, Matsusaki K, et al. DNA methylation status of hMLH1, p16(INK4a), and CDH1 is not associated with mRNA expression levels of DNA methyltransferase and DNA demethylase in gastric carcinomas. Oncol Rep. 2001;8:1085–9.
11. Waki T, Tamura G, Tsuichya T, Sato K, Nishizuka S, Motoyama T. Promoter methylation status of E-cadherin, hMLH1, and p16 genes in nonneoplastic gastric epithelia. Am J Pathol. 2002;161:399–403.
12. Dulaem I, Hillissa J, de Caceres II, Al-Saleem T, Cairns P. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res. 2004;10:6189–93.
13. Kounangnoye RB, Andi T, Taubenslag KJ, Zilberman ST, Taylor CI, Loomans HA, Andi CD. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells. Mol Cancer. 2015;14(1):1–10.
14. Lujambio A, Calin GA, Villanueva A, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA. 2008;105(36):13556–61.
15. Wilting SM, van Boerdonk RA, Henken FE, et al. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer. 2010;9:167.
16. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA. 2008;105:7004–9.
17. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353:1793–801.
18. Saini HK, Griffiths-Jones S, Enright AJ. Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci USA. 2007;104:17719–24.
19. Aguda BD, Kim Y, Piper-Hunter MG, Friedman A, Marsh CB. MiRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. Proc Natl Acad Sci USA. 2008;105:19678–83.
20. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007;39:673–7.
21. Stein RA. DNA methylation profiling: a promising tool and a long road ahead for clinical applications. Int J Clin Pract. 2011;65(12):1212–3.
22. Gattollati CH, Uguen A, Pessonn M, Tillett K, Simon B, Doucet L, Robaszkiewicz M, Corcos L. MicroRNA and targeted mRNA expression profiling analysis in human colorectal adenomas and adenocarcinomas. Eur J Cancer. 2015;51(13):409–20.
23. Shen R, Pan S, Qi S, Lin X, Cheng S. Epigenetic repression of microRNA-129–2 leads to overexpression of SOX4 in gastric cancer. Biochem Biophys Res Commun. 2010;394:1047–52.
24. Corney DC, Hwang CI, Matozo A, Vogt M, Flesken-Nikitin A, Godwin AK, Katam AA, Sood AK, Ellenson LH, Heremeking H, Nistikin AY. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res. 2010;16:1119–28.
25. Huang YW, Liu JC, Deatherage DE, Luo J, Mitch DG, Goodfellow PJ, Miller DS, Huang TH. Epigenetic repression of microRNA-129–2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res. 2009;69:9038–46.
26. Pang KJ, Yoshida M, Zhang XH. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev. 2011;25:326–31.
27. Wang Y, Zhao W, Fu Q. MiR-335 suppresses migration and invasion by targeting ROCK1 in osteosarcoma cells. Mol Cell Biochem. 2013;381:887–97.
28. Xie Y, Wang F, Wang Z, Song Y, Luo Y, Zhang X, et al. MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting BCL-w and specificity protein 1. Oncogene. 2012;31:1398–407.
29. Panigrahi S, Stetefeld J, Jaganneddy JR, Mandal S, Mandal SK, et al. Modeling of molecular interaction between apoptin, BCR-ABL and CrkL—an alternative approach to conventional rational drug design. PLoS ONE. 2012;7:e28395.
30. Singer CF, Hudelist G, Lamm W, Mueller R, Handl C, et al. Active (p) CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition. Oncol Rep. 2006;15:353–9.
31. Yeung CL, Ngo VN, Grohar PJ, Almalez FJ, Asante A, et al. Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Oncogene. 2013;32:5429–38.
32. Kim YH, Kwee KA, Girard L, Salarik K, Kao J, et al. Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer. Oncogene. 2010;29:1421–30.
33. Natsume H, Shimura K, Tao H, Igarashi H, Suzuki M, et al. The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer. J Transl Med. 2012;10:97.